Eric Dane, known for 'Grey's Anatomy' and 'Euphoria,' shares his ALS journey, including loss of function, family support, and determination to not let the disease define him.
BioNTech to acquire German rival CureVac in $1.25B all-stock deal, bolstering its mRNA capabilities.
Eric Dane, known for 'Grey's Anatomy' and 'Euphoria,' shares his ALS journey, including loss of function, family support, and determination to not let the disease define him.
BioNTech to acquire German rival CureVac in $1.25B all-stock deal, bolstering its mRNA capabilities.